Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
141 questions in 31 reviews · Emergency and Critical Care
current versionsNo studies 141 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Oxygenation vs no oxygenation during the apnoeic period preceding intubation Hospital stay · people requiring tracheal intubation Oxygenation during the apnoeic phase preceding intubation in adults in prehospital, emergency department,… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes, Time point of assessment · relatives, patients, and healthcare professionals during resucitation Family presence during resuscitation (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Â · relatives, patients, and healthcare professionals during resucitation Family presence during resuscitation (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo All‐cause mortality D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Siltuximab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Siltuximab vs standard care/placebo Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Levilimab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Levilimab vs standard care/placebo WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants vs no treatment Mortality related to COVID‐19 · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants vs no treatment Adverse events (minor bleeding) · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Mortality related to COVID‐19 · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants vs no treatment Necessity for additional respiratory support · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs standard care/placebo Clinical improvement D60 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs standard care/placebo WHO Clinical Progression Score of level 7 or above D60 or above Interleukin‐1 blocking agents for treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Systemic reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Any adverse event Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Serious adverse events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo Local reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme Confirmed symptomatic COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Heterologous vaccination scheme vs homologous vaccination scheme All‐cause mortality Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Confirmed symptomatic COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Any adverse event Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Booster vs placebo/no booster Serious adverse events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
CVnCoV – CureVac AG vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
ChAdOx1 – AstraZeneca + University of Oxford vs placebo Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford Confirmed symptomatic COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of Oxford vs ChAdOx1 – University of Oxford All‐cause mortality Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
AD26.COV2.S – Janssen Pharmaceutical Companies vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Gam‐COVID‐VAC – Sputnik V vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo Systemic reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Gam‐COVID‐VAC – Sputnik V vs placebo Systemic reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Gam‐COVID‐VAC – Sputnik V vs placebo Any adverse event Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
Gam‐COVID‐VAC – Sputnik V vs placebo Local reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
CoronaVac – Sinovac vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
WIBP‐CorV – Sinopharm‐Wuhan vs placebo Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
WIBP‐CorV – Sinopharm‐Wuhan vs placebo All‐cause mortality Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
BBIBP‐CorV – Sinopharm‐Beijing vs placebo Severe or critical COVID‐19 Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
BBIBP‐CorV – Sinopharm‐Beijing vs placebo All‐cause mortality Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo Local reactogenicity events Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |
NVX‐CoV2373 – Novavax vs placebo Confirmed SARS‐CoV‐2 infection Efficacy and safety of COVID‐19 vaccines (2022) · Cochrane | no estimate extracted | NR | No studies |